ABOS
Price
$1.44
Change
+$0.06 (+4.35%)
Updated
Sep 5 closing price
Capitalization
87.23M
72 days until earnings call
SKYE
Price
$4.00
Change
+$0.25 (+6.67%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
123.95M
Interact to see
Advertisement

ABOS vs SKYE

Header iconABOS vs SKYE Comparison
Open Charts ABOS vs SKYEBanner chart's image
Acumen Pharmaceuticals
Price$1.44
Change+$0.06 (+4.35%)
Volume$114.66K
Capitalization87.23M
Skye Bioscience
Price$4.00
Change+$0.25 (+6.67%)
Volume$13.38K
Capitalization123.95M
ABOS vs SKYE Comparison Chart in %
Loading...
ABOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ABOS vs. SKYE commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ABOS is a Hold and SKYE is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (ABOS: $1.38 vs. SKYE: $3.75)
Brand notoriety: ABOS and SKYE are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ABOS: 25% vs. SKYE: 136%
Market capitalization -- ABOS: $87.23M vs. SKYE: $123.95M
ABOS [@Biotechnology] is valued at $87.23M. SKYE’s [@Biotechnology] market capitalization is $123.95M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ABOS’s FA Score shows that 0 FA rating(s) are green whileSKYE’s FA Score has 0 green FA rating(s).

  • ABOS’s FA Score: 0 green, 5 red.
  • SKYE’s FA Score: 0 green, 5 red.
According to our system of comparison, SKYE is a better buy in the long-term than ABOS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ABOS’s TA Score shows that 3 TA indicator(s) are bullish while SKYE’s TA Score has 5 bullish TA indicator(s).

  • ABOS’s TA Score: 3 bullish, 5 bearish.
  • SKYE’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, SKYE is a better buy in the short-term than ABOS.

Price Growth

ABOS (@Biotechnology) experienced а +5.34% price change this week, while SKYE (@Biotechnology) price change was +7.76% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.44%. For the same industry, the average monthly price growth was +9.90%, and the average quarterly price growth was +31.78%.

Reported Earning Dates

ABOS is expected to report earnings on Nov 17, 2025.

Industries' Descriptions

@Biotechnology (+2.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
SKYE($124M) has a higher market cap than ABOS($87.2M). SKYE YTD gains are higher at: 32.509 vs. ABOS (-16.279). SKYE has higher annual earnings (EBITDA): -41.68M vs. ABOS (-132.35M). ABOS has more cash in the bank: 143M vs. SKYE (48.6M). SKYE has less debt than ABOS: SKYE (368K) vs ABOS (30.1M). ABOS (0) and SKYE (0) have equivalent revenues.
ABOSSKYEABOS / SKYE
Capitalization87.2M124M70%
EBITDA-132.35M-41.68M318%
Gain YTD-16.27932.509-50%
P/E RatioN/A3.57-
Revenue00-
Total Cash143M48.6M294%
Total Debt30.1M368K8,179%
FUNDAMENTALS RATINGS
SKYE: Fundamental Ratings
SKYE
OUTLOOK RATING
1..100
8
VALUATION
overvalued / fair valued / undervalued
1..100
37
Fair valued
PROFIT vs RISK RATING
1..100
100
SMR RATING
1..100
98
PRICE GROWTH RATING
1..100
47
P/E GROWTH RATING
1..100
97
SEASONALITY SCORE
1..100
90

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

TECHNICAL ANALYSIS
Technical Analysis
ABOSSKYE
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bullish Trend 1 day ago
73%
Bullish Trend 2 days ago
89%
Momentum
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 2 days ago
88%
MACD
ODDS (%)
Bearish Trend 1 day ago
86%
Bullish Trend 2 days ago
80%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 2 days ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
79%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
Bullish Trend 19 days ago
78%
Bullish Trend 8 days ago
86%
Declines
ODDS (%)
Bearish Trend 9 days ago
88%
Bearish Trend 3 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 2 days ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
ABOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
SKYE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
OPMXF0.940.04
+4.42%
OPERADORA DE SITES MEXICANOS S A B DE C V
CVPBF1.28N/A
N/A
C.P. All Public Co Ltd
NRPI0.08N/A
N/A
NRP Stone, Inc.
CCCP0.05N/A
N/A
Crona Corp.
PBTHF0.80-0.05
-5.76%
PointsBet Holdings Limited

ABOS and

Correlation & Price change

A.I.dvisor indicates that over the last year, ABOS has been loosely correlated with KYTX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ABOS jumps, then KYTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ABOS
1D Price
Change %
ABOS100%
+4.35%
KYTX - ABOS
46%
Loosely correlated
+8.54%
CRBU - ABOS
45%
Loosely correlated
+1.08%
BEAM - ABOS
45%
Loosely correlated
+12.62%
FHTX - ABOS
45%
Loosely correlated
+7.05%
GLSI - ABOS
44%
Loosely correlated
-0.36%
More

SKYE and

Correlation & Price change

A.I.dvisor indicates that over the last year, SKYE has been loosely correlated with CRBP. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if SKYE jumps, then CRBP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SKYE
1D Price
Change %
SKYE100%
+11.61%
CRBP - SKYE
48%
Loosely correlated
+1.73%
JANX - SKYE
40%
Loosely correlated
+3.91%
VKTX - SKYE
34%
Loosely correlated
-1.12%
ABOS - SKYE
32%
Poorly correlated
-0.72%
NKTR - SKYE
31%
Poorly correlated
+26.02%
More